Liver News and Research

RSS

Loyola forms new sixth research-focused transplant institute at LUHS

From the world's first successful kidney transplant to the first successful heart transplant performed in Illinois, Loyola University Health System has always been a pioneer in organ transplant research, education and clinical care.

21 Feb 2011

International study shows reprogramming cells lead to genomic aberrations

It's a discordant note in the symphony of good news that usually accompanies stem cell research announcements. Stem cells hold enormous promise in regenerative medicine, thanks to their ability to regenerate diseased or damaged tissues.

21 Feb 2011

Scientists use synthetic oil for dispersing pathogenic fungi to prevent malaria spread

There are over 200 million cases of malaria each year and, according to the World Health Organisation, in 2009 malaria was responsible for 781,000 deaths worldwide. Malaria is spread by mosquitoes which breed in open water and spend much of their larval stage feeding on fungi and microorganisms at the water surface.

20 Feb 2011

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Protalix BioTherapeutics, Inc., announced today that new clinical data from the switchover trial of taliglucerase alfa in Gaucher disease patients and preclinical data on oral enzyme glucocerebrosidase (oral GCD) will be presented today at the 7th Annual Meeting of the Lysosomal Disease Network: WORLD Symposium 2011 in Las Vegas, Nevada.

19 Feb 2011

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint.

19 Feb 2011

Québec-Transplant: 371 persons benefited from transplant in 2010

Thanks to 119 deceased organ donors, 371 persons benefited from a transplant in 2010. Unfortunately, there were also 46 deaths among people on the waiting list (compared to 58 in 2009), many of which could have been avoided. As of December 31, 2010, 1,241 people were registered on the single waiting list managed by Québec-Transplant.

19 Feb 2011

Doctor explores link between lack of oxygen and inflammation in patients undergoing surgery

When the body is deprived of oxygen during a major surgery, the kidneys, heart muscles or lungs can be injured as a result. The problem is that lack of oxygen can lead to inflammation.

19 Feb 2011

USPTO issues two patents to VIRxSYS SMaRT RNA platform technology

VIRxSYS Corporation, a privately-held biotechnology company with proprietary RNA payload and lentiviral vector delivery platform technologies, today announced that the United States Patent and Trademark Office has issued the Company two patents for its SMaRT RNA platform technology, capable of reprogramming or repairing genes to create, increase or change protein expression.

18 Feb 2011

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, notes that its development partner, Tibotec Pharmaceuticals, announced today that the global phase 3 studies with TMC435 in treatment-naive patients and patients who have relapsed after prior SOC treatment have started.

18 Feb 2011

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Exelixis, Inc. today reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer (CRPC) treated with cabozantinib (XL184) in an ongoing phase 2 adaptive randomized discontinuation trial.

18 Feb 2011

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

Apricus Biosciences, Inc., announced today that it is currently in discussions with the U.S. Food and Drug Administration ("FDA") relating to the PrevOnco™ Special Protocol Assessment ("SPA") Phase III protocol submitted by the Company in December 2010.

18 Feb 2011

U.S. FDA approves Corifact to prevent bleeding in people with Factor XIII deficiency

The U.S. Food and Drug Administration today approved Corifact, the first product intended to prevent bleeding in people with the rare genetic defect congenital Factor XIII deficiency.

18 Feb 2011

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Conatus Pharmaceuticals Inc. announced today the treatment of the first patient in a multi-center Phase 2b clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a and ribavirin in a treatment experienced, hepatitis C null responder patient population. Safety, tolerability, and antiviral activity of the triple combination will be assessed after up to 48 weeks of therapy.

18 Feb 2011

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Progenics Pharmaceuticals, Inc. today reported positive preliminary data from an ongoing phase 1 study of PSMA ADC, an antibody-drug conjugate designed to selectively deliver chemotherapy to cells that express prostate-specific membrane antigen.

17 Feb 2011

Researchers find blue-green algae may be responsible for producing estrogen-like compound in water

University of Tennessee, Knoxville, researchers have found that blue-green algae may be responsible for producing an estrogen-like compound in the environment which could disrupt the normal activity of reproductive hormones and adversely affect fish, plants and human health.

17 Feb 2011

Unrecognized substances released by algae blooms may act as endocrine disruptors

Scientists are reporting for the first time that previously unrecognized substances released by algae blooms have the potential to act as endocrine disruptors, which can interfere with the normal activity of reproductive hormones. The effect is not caused by microcystin toxins, long recognized as potentially harmful to humans and aquatic animals, but as yet unidentified substances.

17 Feb 2011

Study sheds light on novel functions of certain PCSK enzymes

Recent studies conducted at the Institut de recherches cliniques de Montr-al on a group of PCSK enzymes could have a positive impact on health, from cholesterol to osteoporosis.

17 Feb 2011

First lung cancer treatment with BSD's MicroThermX ablation system delivered at Rhode Island Hospital

BSD Medical Corporation today announced the successful delivery of its first lung cancer patient treatment with the MicroThermX® Microwave Ablation System. The treatment was conducted by Damian E. Dupuy, M.D., at The Comprehensive Cancer Center at Rhode Island Hospital in Providence, Rhode Island.

16 Feb 2011

CPIC scientists find rates of liver cancer in US-born Hispanic men increased by 87%

Thirty-year-old Pedro Espinosa's chances of developing liver cancer just skyrocketed. Born in the United States and of Hispanic descent, Pedro falls into a category of men in California whose liver cancer rates have nearly doubled over the past two decades, according to a recent study.

16 Feb 2011

Study: High bilirubin levels within normal range linked with reduced risk of respiratory diseases

An analysis of data including more than 500,000 adults indicates that levels in the blood of bilirubin in the normal range but relatively higher were associated with a reduced risk of lung cancer, chronic obstructive pulmonary disease and all-cause death, according to a study in the February 16 issue of JAMA.

15 Feb 2011

Liver News and Research

Loyola forms new sixth research-focused transplant institute at LUHS

International study shows reprogramming cells lead to genomic aberrations

Scientists use synthetic oil for dispersing pathogenic fungi to prevent malaria spread

Protalix: New data from taliglucerase alfa, oral GCD trials to be presented at Lysosomal Disease Network Symposium

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Québec-Transplant: 371 persons benefited from transplant in 2010

Doctor explores link between lack of oxygen and inflammation in patients undergoing surgery

USPTO issues two patents to VIRxSYS SMaRT RNA platform technology

Tibotec begins enrollment in TMC435 phase 3 trial for treatment of HCV

Positive interim data from cabozantinib Phase 2 metastatic castration-resistant prostate cancer trial

Apricus Bio in discussions with FDA for PrevOnco SPA Phase III protocol

U.S. FDA approves Corifact to prevent bleeding in people with Factor XIII deficiency

Conatus commences multi-center CTS-1027 Phase 2b trial for HCV treatment

Positive preliminary data from ongoing PSMA ADC phase 1 study against prostate cancer

Researchers find blue-green algae may be responsible for producing estrogen-like compound in water

Unrecognized substances released by algae blooms may act as endocrine disruptors

Study sheds light on novel functions of certain PCSK enzymes

First lung cancer treatment with BSD's MicroThermX ablation system delivered at Rhode Island Hospital

CPIC scientists find rates of liver cancer in US-born Hispanic men increased by 87%

Study: High bilirubin levels within normal range linked with reduced risk of respiratory diseases

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News